Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis
Authors' conclusion
Overall, orforglipron demonstrated clinically meaningful metabolic benefits with an acceptable safety profile.
Study context
- Population
- Obese adults with and without diabetes; 4 databases searched through November 2025
- Participants
- 6,140 adults5 RCTs
- Comparison
- Once-daily oral orforglipron by dose, in adults with and without diabetes
- Outcome
- Body weight
Pooled result
As reported in the abstract
- Consistent, dose-dependent reductions in body weight
- Weight reduction with DM: modest at 3 mg to more than 6 kg at 36 mg
- Weight reduction without DM: greater, approaching 12 kg at the highest dose
Further pooled results
- HbA1c
- −1.29%
- Significant improvements in BMI, waist circumference and HbA1c
Safety
- Gastrointestinal AEs increased with higher dose
- No significant difference in incidence of acute pancreatitis
Original publication
Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis. Diabetes Technol Ther. Published 4 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →